This study looks at a new treatment, called F01, for people with a type of cancer called non-Hodgkin's lymphoma. This cancer affects the lymphatic system, an important part of our immune system. The study is for patients whose cancer has come back (relapsed) or didn’t respond to treatment (refractory). This is a **Phase I study**, meaning researchers are checking if the treatment is safe and how much can be given. The study will have about 55 people and is in two parts: testing different doses, and then using the best dose found. Participants need to be at least 18 years old and have specific types of non-Hodgkin's lymphoma. They must have had certain previous treatments and still have signs of the disease. Some health conditions may prevent someone from joining, like certain allergies or other serious health issues. **Key Points:** - **Duration**: The study is ongoing and involves multiple phases. - **Visits**: Participants will undergo several appointments for monitoring. - **Risks**: Risks include possible side effects from the new treatment, which are still being studied. Participants will be monitored closely to ensure safety, and findings will help determine if F01 is an effective treatment option.